Surface the highest-value molecule adjacencies for an API manufacturer's existing portfolio. Rising lane HHI in core destinations where a second source clears institutional demand.
The lane-competitiveness scan returns 20 high-conviction adjacency candidates where 2024 HHI rose at least 500 points over 2023 and the lane carries enough declared volume to absorb a fourth or fifth credible exporter. Rivaroxaban into Somalia, atorvastatin into Singapore, and vildagliptin into Iraq are the loudest signals for a cardiometabolic-API maker with India-based capacity.
| # | Molecule | Lane | 2024 HHI | HHI rise | Active exporters |
|---|---|---|---|---|---|
| 1 | Rivaroxaban | → Somalia · ROW | 9432 HHI | +8,100 vs 2023 | 6 exporters · top-3 99% |
| 2 | Atorvastatin | → Singapore · regional hub | 9084 HHI | +8,070 vs 2023 | 9 exporters · top-3 100% |
| 3 | Mometasone furoate | → Somalia · ROW | 9150 HHI | +8,024 vs 2023 | 5 exporters · top-3 100% |
| 4 | Levetiracetam | → Ghana · Sub-Saharan | 9238 HHI | +7,940 vs 2023 | 5 exporters · top-3 99% |
| 5 | Levetiracetam | → Singapore · regional hub | 9259 HHI | +7,748 vs 2023 | 6 exporters · top-3 100% |
| 6 | Vildagliptin | → Iraq · regional | 8940 HHI | +7,393 vs 2023 | 7 exporters · top-3 98% |
| 7 | Dapagliflozin | → Nigeria · Sub-Saharan | 9489 HHI | +7,352 vs 2023 | 6 exporters · top-3 100% |
| 8 | Oxaliplatin | → Sri Lanka · regional | 9648 HHI | +7,280 vs 2023 | 5 exporters · top-3 99% |
| 9 | Montelukast | → Cyprus · EU-adjacent | 9147 HHI | +6,979 vs 2023 | 5 exporters · top-3 99% |
| 10 | Mycophenolate mofetil | → Thailand · regional | 9432 HHI | +6,949 vs 2023 | 5 exporters · top-3 99% |
| 11 | Clarithromycin | → Cyprus · EU-adjacent | 9057 HHI | +6,915 vs 2023 | 5 exporters · top-3 99% |
| 12 | Enzalutamide | → Turkey · regional | 9867 HHI | +6,717 vs 2023 | 6 exporters · top-3 100% |
Type the therapy areas or specific molecules you currently make. The AI agent matches your portfolio against the molecule catalog and pulls your core destination markets.
Across molecules outside your portfolio, finds lanes in your core destinations where 2024 HHI rose meaningfully over 2023 and the active cohort is small enough that a credible new entrant clears demand.
Citation-anchored ranking of molecule adjacencies with HHI delta, exporter count, and a regulatory-prerequisite chip per row. Routes directly to DMF and CEP filing-status views.
When lane concentration is increasing, the buyer cohort is anxious about over-reliance on the incumbent set. A credible 4th to 6th exporter clears the procurement bid.
Adjacencies are filtered to the destinations where you already have commercial relationships, not the global universe. The first ship is easier when the lane is already familiar.
FDA Type II DMF status, EDQM CEP status, marketing authorisation holder, ANVISA registration. The gating signals for entering each lane sit on the row.
Trade flows refresh weekly. Lanes where HHI crossed the threshold this week move to the top of the brief; lanes that softened drop off.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Count of qualifying rising-HHI adjacencies by therapy class · 2024 trade warehouse · for a cardiometabolic-API maker.
Portfolio expansion is the second-question for any API manufacturer past initial scale: where does my next molecule slot fit, given my existing markets and the lane dynamics there? PharmaDB scans rising-HHI lanes globally, filters to a supplier’s core destinations, and ranks by entry tractability. The view is lane_competitiveness; the join is to molecule_country_flow and the molecule catalog. Refresh cadence is weekly.
Rising concentration means the incumbent cohort is consolidating. The buyer cohort on that lane (institutional, formulator, hospital) starts to feel single-supplier risk and opens a slot for a credible second source. The bigger the HHI rise, the louder the implicit invitation.
The AI agent matches your portfolio to its therapy class and destination footprint. Adjacencies are molecules in the same or neighbouring therapy class with lane activity in destinations where you already ship. Cross-class jumps are flagged as expansion, not adjacency.
Yes. Each row carries a prerequisite chip from the joined filing-status views: FDA Type II DMF status, EDQM CEP status, marketing authorisation holder of record. Clicking the chip routes to the filing-status view for that molecule-region.
An HHI below 2,500 is the DOJ-equivalent 'moderately concentrated' zone. The lane is already distributed enough that a new entrant fights a price war. Adjacency value sits where HHI is high enough to invite a second source but not so high that the anchor is locked in by qualification.
Global. The scan covers every lane in `lane_competitiveness` across all destinations. The result is filtered to the destinations matching your portfolio, then ranked by HHI rise. The US shows up but does not dominate; institutional-channel and regional-hub lanes consistently appear in the top tier.
Weekly. Trade aggregates and lane competitiveness recompute on every refresh; the adjacency rank reranks. The catalog row carries the exact computation timestamp.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.